Victory Financial Group LLC Invests $754,000 in Tempus AI, Inc. $TEM

Victory Financial Group LLC purchased a new stake in shares of Tempus AI, Inc. (NASDAQ:TEM) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 12,771 shares of the company’s stock, valued at approximately $754,000.

Several other hedge funds have also recently bought and sold shares of TEM. Renaissance Capital LLC increased its holdings in shares of Tempus AI by 26.9% in the 3rd quarter. Renaissance Capital LLC now owns 84,166 shares of the company’s stock valued at $6,793,000 after purchasing an additional 17,866 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in Tempus AI by 1,459.8% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 101,276 shares of the company’s stock valued at $8,174,000 after purchasing an additional 94,783 shares in the last quarter. Hussman Strategic Advisors Inc. acquired a new position in Tempus AI in the 3rd quarter valued at approximately $1,695,000. Vanguard Group Inc. increased its stake in Tempus AI by 22.1% in the 3rd quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company’s stock valued at $762,032,000 after buying an additional 1,706,837 shares during the period. Finally, Krane Funds Advisors LLC lifted its position in Tempus AI by 218.2% in the 3rd quarter. Krane Funds Advisors LLC now owns 28,230 shares of the company’s stock worth $2,427,000 after buying an additional 19,358 shares in the last quarter. 24.22% of the stock is owned by hedge funds and other institutional investors.

Tempus AI Stock Performance

Shares of NASDAQ TEM opened at $47.03 on Thursday. The business’s 50-day simple moving average is $53.75 and its 200-day simple moving average is $68.82. The company has a debt-to-equity ratio of 2.52, a quick ratio of 3.00 and a current ratio of 3.13. Tempus AI, Inc. has a 52 week low of $36.22 and a 52 week high of $104.32. The firm has a market cap of $8.41 billion, a price-to-earnings ratio of -33.35 and a beta of 4.87.

Insider Activity

In related news, CEO Ryan Fukushima sold 9,592 shares of the company’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $59.05, for a total transaction of $566,407.60. Following the completion of the sale, the chief executive officer directly owned 694,354 shares of the company’s stock, valued at approximately $41,001,603.70. This represents a 1.36% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Ryan M. Bartolucci sold 2,902 shares of the firm’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $59.05, for a total transaction of $171,363.10. Following the completion of the transaction, the chief accounting officer owned 41,159 shares in the company, valued at $2,430,438.95. The trade was a 6.59% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 568,841 shares of company stock valued at $32,579,611. Insiders own 26.27% of the company’s stock.

Key Stories Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: ALERT trial with Medtronic shows Tempus’ AI-driven EHR alerts improved timely evaluation and treatment for aortic stenosis and mitral regurgitation across multiple health systems — evidence the company can convert real-world data/AI into measurable care improvements that support commercial adoption. Tempus and Medtronic Announce ALERT Trial Results Showing AI-Driven EHR Notifications Improve Treatment for Significant Valvular Heart Disease
• Positive Sentiment: Diagnostics segment set for strong 2026 growth driven by oncology test demand, expanding minimal residual disease (MRD) adoption, higher pricing and improving reimbursement — a near-term revenue and margin tailwind for Tempus’ core business. What’s Fueling TEM Diagnostics Segment’s Strong 2026 Outlook?
• Positive Sentiment: Collaboration with Daiichi Sankyo targets precision oncology drug development (antibody drug conjugate program) using Tempus’ multimodal AI and RWD — validates Tempus’ platform to support large pharma trials and could accelerate commercial partnerships and revenue through sponsor-led programs. Tempus AI Daiichi Sankyo Tie Up Highlights Precision Oncology Opportunity
• Positive Sentiment: Bullish investor write-ups highlight Tempus’ massive data asset (cited ~450 petabytes) and AI models as a durable moat with upside from model monetization and diagnostics growth — supports valuation narratives for long-term growth investors. Tempus AI: 450-Petabyte Moat, High-Growth Upside At A Discount
• Neutral Sentiment: High-profile media commentary is mixed: Jim Cramer called TEM “a decent spec” and suggested holding some shares rather than all — useful for retail sentiment but not a fundamental change. Jim Cramer on Tempus AI: “It’s a Decent Spec, I Would Hold on to Some, But Not All”
• Neutral Sentiment: Comparisons and analyst pieces (TEM vs. peers like DOCS/SDGR) highlight both upside from AI/RWD and the question of sustainable monetization — useful framing for relative valuation and competitive risk. TEM vs. DOCS: Which Medical Info Systems Stock Is the Better Pick Now?
• Negative Sentiment: Risk factors that could cap the stock: negative GAAP profitability (negative P/E), high debt-to-equity (2.52), elevated beta (~5.3) and the share price sitting below the 50- and 200-day moving averages — signals of execution/volatility risk that can amplify sell-offs if growth/reimbursement or partnership milestones slip.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on TEM. BTIG Research lowered their price target on shares of Tempus AI from $105.00 to $90.00 and set a “buy” rating on the stock in a report on Wednesday, February 25th. Needham & Company LLC reissued a “buy” rating and set a $75.00 price objective on shares of Tempus AI in a research report on Wednesday, March 11th. HC Wainwright boosted their target price on Tempus AI from $89.00 to $95.00 and gave the company a “buy” rating in a research note on Monday, March 9th. Stifel Nicolaus set a $60.00 target price on Tempus AI in a research report on Wednesday, February 25th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tempus AI in a research note on Thursday, January 22nd. Eight analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Tempus AI has an average rating of “Moderate Buy” and a consensus target price of $75.92.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.